Cellular and gene therapy for major histocompatibility complex class II deficiency

News in Physiological Sciences

Volumn 19, Issue 3, 2004, Pages 154-158

  Matheux, Franck ^a,b   Villard, Jean ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; HLA ANTIGEN CLASS 2;

ADOPTIVE IMMUNOTHERAPY; CELL BASED GENE THERAPY; GENE; GENE CONTROL; GENETIC DISORDER; IMMUNE DEFICIENCY; LENTIVIRUS VECTOR; MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II DEFICIENCY; NONHUMAN; REVIEW; ANIMAL; COMBINED IMMUNODEFICIENCY; GENE THERAPY; GENETICS; HUMAN;

ANIMALS; GENE THERAPY; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 3042721509     PISSN: 08861714     EISSN: None     Source Type: Journal    
DOI: 10.1152/nips.01462.2003     Document Type: Review

References (18)

1. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, and Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672, 2000.
2. Chang CH, Guerder S, Hong SC, van Ewijk W, and Flavell RA. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 4: 167-178, 1996.
3. Clausen B, Waldburger J, Schwenk F, Barras E, Mach B, Rajewski K, Förster I, and Reith W. Residual MHC class II expression on mature dendritic cells and activated B cells in RFX5-deficient mice. Immunity 8: 143-155, 1998.
4. Durand B, Sperisen P, Emery P, Barras E, Zufferey M, Mach B, and Reith W. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J 16: 1045-1055, 1997.
5. Fischer A. Primary immunodeficiency diseases: an experimental model for molecular medicine. Lancet 357: 1863-1869, 2001.
6. Hacein BA, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, and Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348: 255-256, 2003.
7. Klein C, Cavazzana-Calvo M, Le Deist F, Jabado N, Benkerrou M, Blanche S, Lisowska-Grospierre B, and Griscelli C. Bone marrow transplantation in major histocompatibility complex class II deficiency: a single-center study of 19 patients. Blood 85: 580-587, 1995.
8. Masternak K, Barras E, Zufferey M, Conrad B, Corthals G, Aebersold R, Sanchez JC, Hochstrasser DF, Mach B, and Reith W. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 20: 273-277, 1998.
9. Matheux F, Ikinciogullari A, Zapata DA, Barras E, Zufferey M, Dogu F, Regueiro JR, Reith W, and Villard J. Direct genetic correction as a new method for diagnosis and molecular characterization of MHC class II deficiency. Mol Ther 6: 824-829, 2002.
10. Peretti M, Villard J, Barras E, Zufferey M, and Reith W. Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP. Mol Cell Biol 21: 5699-5709, 2001.
11. Reith W and Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 19: 331-373, 2001.
12. Salmon P, Kindler V, Ducrey O, Chapuis B, Zubler RH, and Trono D. High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 96: 3392-3398, 2000.
13. Steimle V, Durand B, Barras E, Zufferey M, Hadam MR, Mach B, and Reith W. A novel DNA binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev 9: 1021-1032, 1995.
14. Steimle V, Otten LA, Zufferey M, and Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75: 135-146, 1993.
15. Uchida N, Tsukamoto A, He D, Friera AM, Scollay R, and Weissman IL. High doses of purified stem cells cause early hematopoietic recovery in syngeneic and allogeneic hosts. J Clin Invest 101: 961-966, 1998.
16. Villard J, Lisowska-Grospierre B, Van den Elsen P, Fischer A, Reith W, and Mach B. Mutation of RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency. N Engl J Med 337: 748-753, 1997.
17. Villard J, Masternak K, Lisowska-Grospierre B, Fischer A, and Reith W. MHC class II deficiency: a disease of gene regulation. Medicine (Baltimore) 80: 405-418, 2001.
18. Villard J, Peretti M, Masternak K, Barras E, Caretti G, Mantovani R, and Reith W. A functionally essential domain of RFX5 mediates activation of major histocompatibility complex class II promoters by promoting cooperative binding between RFX and NF-Y. Mol Cell Biol 20: 3364-3376, 2001.